Generalist investors that gambled on the US biopharmaceutical initial public offering market between 2013 and mid-2015 are largely gone, leaving health care specialists to bet on less risky drug developer IPOs in 2016 – a trend that’s expected to continue in 2017.
US IPOs In Review: Relatively Muted Market In 2016 To Continue In 2017
After biopharma initial public offerings in the US during 2016 outperformed the prior year’s IPOs, expect more of the same in 2017: fewer, but higher quality offerings at lower IPO share prices to keep values at acceptable levels for experienced health care investors.
More from Start-Ups & SMEs
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The Belgian firm banks nearly €77.7m to push its Charcot-Marie-Tooth to proof-of-concept.
• By
Deal Snapshot: The antibody-drug conjugate field continues one of the hottest dealmaking spaces and Roche continues to invest heavily. Its latest pact could be transformative for the UK firm which already has a decent number of big pharma partners.
• By
The potential first-in-class antibody oligonucleotide conjugate could treat a form of the muscle wasting disease, and could be the first of Avidity’s trio of rare disease drugs to gain approval.
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.